Lenz, H.J., Van Cutsem, E., Khambata-Ford, S., et al. (2006) Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. Journal of Clinical Oncology, 24, 4914-4921.
https://doi.org/10.1200/JCO.2006.06.7595

has been cited by the following article:

• TITLE: Benefit of Targeted Therapies in Metastatic Colon Cancer in the Ivorian Context

  AUTHORS: Touré Moctar, Kouassi Kouamé K. Yvon, Séka E. Narcisse, Traoré Kady, Kimso Oumou, Niang D. Rokhaya, Odo B. Adde, Oseni Jelili, Adoubi Innocent

  KEYWORDS: Cancer-Colon-Metastasis-Targeted Therapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.8, August 15, 2017

  ABSTRACT: In our daily practice, the use of targeted therapies (Bevacizumab and rarely Cetuximab) in metastatic colic cancers is recent. Very few patients benefit from these therapies because of their high cost. In a cohort of 68 patients who received these therapies, a retrospective and prospective study was conducted over three years period (1 January 2013 to 31 December 2015) to evaluate their benefit in terms of quality of life, tolerance and overall survival. These targeted therapies provided a significant clinical and biological gain with acceptable toxicities (most often resolving spontaneously). Moreover, they have allowed a significant improvement in overall survival in first line metastatic treatment. The limiting factor remains their extremely high cost and therefore inaccessibility to the majority of our patients.